Next Article in Journal
Non-Canonical WNT/Wnt5a Pathway Activity in Circulating Monocytes of Untreated Psoriatic Patients: An Exploratory Study of Its Association with Inflammatory Cytokines and Cardiovascular Risk Marker-ADAMTS7
Previous Article in Journal
Spacer-Supported Thermal Ablation to Prevent Carbonisation and Improve Ablation Size: A Proof of Concept Study
Previous Article in Special Issue
Combination of Conventional Drugs with Biocompounds Derived from Cinnamic Acid: A Promising Option for Breast Cancer Therapy
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomedicines
Volume 11
Issue 2
10.3390/biomedicines11020576
Review Report
biomedicines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

CXCR1: A Cancer Stem Cell Marker and Therapeutic Target in Solid Tumors

Biomedicines 2023, 11(2), 576; https://doi.org/10.3390/biomedicines11020576
by Caitlin Molczyk and Rakesh K. Singh *
Reviewer 1:
Wen-Wei Chang
Reviewer 2: Anonymous
Biomedicines 2023, 11(2), 576; https://doi.org/10.3390/biomedicines11020576
Submission received: 30 January 2023 / Revised: 10 February 2023 / Accepted: 14 February 2023 / Published: 16 February 2023
(This article belongs to the Special Issue Tumor Microenvironment Regulation and Anti-cancer Natural Products)

Round 1

Reviewer 1 Report

From the 4th paragraph (CXCR1 and CXCR2: Potential different roles), the authors claimed the CXCR1, rather than CXCR2, contributes to cancer stem cells. However, CXCR2 has been reported to promote CSCs in breast cancer (https://doi.org/10.3389/fcell.2021.689286), colon cancer ( 

https://doi.org/10.1002/jcp.27891), or hepatocellular carcinoma (https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-022-00881-4). The authors should include CXCR2 in this review article.

Author Response

We have revised our manuscript to include these studies.

Author Response File: Author Response.pdf

Reviewer 2 Report

The authors have written a well summarized review on CXCR1/2 pathway and have illustrated that CXCR1 is gaining popularity as a target for cancer stem cell marker and as a therapeutic target in various cancers including breast cancer, lung cancer, colon cancer etc.

In line 134, the authors state that ‘most known CSC markers do not act as therapeutic targets, including CD44'.

Although CD44 receptor has been widely used as a therapeutic target for cancer stem cells and cancer cells. I would like the authors to revise the sentence and include this recent published article suggesting targeted drug delivery in triple negative breast cancer and colon cancer cell (https://doi.org/10.1021/acs.molpharmaceut.2c00439).

In section for colon cancer section 7.2, authors could also highlight the carcinoembryonic antigen (CEA) which has also been used for targeting CSCs.

Author Response

In line 134, the authors state that ‘most known CSC markers do not act as therapeutic targets, including CD44'. Although CD44 receptor has been widely used as a therapeutic target for cancer stem cells and cancer cells. I would like the authors to revise the sentence and include this recent published article suggesting targeted drug delivery in triple negative breast cancer and colon cancer cell (https://doi.org/10.1021/acs.molpharmaceut.2c00439).

 

We have revised our manuscript to discuss it.

 

In section for colon cancer section 7.2, authors could also highlight the carcinoembryonic antigen (CEA) which has also been used for targeting CSCs.

 

Necessary changes have been made in the revised manuscript.

Author Response File: Author Response.doc

Round 2

Reviewer 1 Report

The authors have greatly improved their manuscript, and I have no more questions.

Back to TopTop